SIRT1 Promotes Chemoradiotherapy Resistance in Esophageal Squamous Cell Carcinoma
Oncology · 2024
DOI: 10.1159/000540247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Hiroki Morishita und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Sirtuin 1, Chemoradiotherapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Introduction
Identifying accurate biomarkers for predicting response to chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) is a critical challenge. The protein SIRT1, recognized for its implications in longevity, has been associated with tumor promotion in ESCC. However, data regarding its correlation with CRT sensitivity remain unreported. Therefore, in this study, we aimed to investigate the relationship between SIRT1 expression and CRT sensitivity and concurrently assess the effect of SIRT1 knockdown on CRT sensitivity in ESCC.
Methods
This study included 73 patients who underwent radical esophagectomy after CRT. SIRT1 expression in pre-treatment endoscopic biopsies was assessed through immunostaining, followed by a comparative analysis of CRT effects on surgical specimens. Small interfering RNA was used to attenuate SIRT1 expression in TE5 and TE10 cells, which were then subjected to cisplatin treatment at varying doses and concentrations and irradiation with X-rays, respectively.
Results
High SIRT1 tissue expression was significantly associated with CRT resistance. Multivariate analysis identified high SIRT1 expression as an independent biomarker for poor CRT response. In TE-5 and TE-10 cells, SIRT1 knockdown significantly decreased cell viability and increased sensitivity to cisplatin and radiation treatment compared to that of the negative control.
Conclusion
Our study results demonstrate the potential of SIRT1 as a predictive biomarker for CRT response in ESCC, highlighting the heightened sensitivity to CRT upon the transcriptional inactivation of SIRT1. Targeting SIRT1 emerges as a promising strategy for enhancing the efficacy of CRT for ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Zitieren
APA
Morishita, H., Otsuka, R., Murakami, K., Endo, S., Toyozumi, T., Matsumoto, Y., Shiraishi, T., Iida, S., Makiyama, T., Nishioka, Y., Hu, J., Maiyulan, A., & Matsubara, H. (2024). SIRT1 Promotes Chemoradiotherapy Resistance in Esophageal Squamous Cell Carcinoma. Oncology. https://doi.org/10.1159/000540247
Vancouver
Morishita H, Otsuka R, Murakami K, Endo S, Toyozumi T, Matsumoto Y, et al. SIRT1 Promotes Chemoradiotherapy Resistance in Esophageal Squamous Cell Carcinoma. Oncology. 2024. doi:10.1159/000540247
BibTeX
@article{Morishita2024,
author = {Morishita, Hiroki and Otsuka, Ryota and Murakami, Kentaro and Endo, Satoshi and Toyozumi, Takeshi and Matsumoto, Yasunori and Shiraishi, Tadashi and Iida, Shinichiro and Makiyama, Tenshi and Nishioka, Yuri and Hu, Jie and Maiyulan, Abula and Matsubara, Hisahiro},
title = {SIRT1 Promotes Chemoradiotherapy Resistance in Esophageal Squamous Cell Carcinoma},
journal = {Oncology},
year = {2024},
doi = {10.1159/000540247}
}
EUVIMED